2018
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal Of The American Society Of Nephrology 2018, 29: 2458-2470. PMID: 30228150, PMCID: PMC6171265, DOI: 10.1681/asn.2018060590.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseOpen-label extension studyProgressive autosomal dominant polycystic kidney diseaseFirst drug treatmentRenal protective measuresKidney function declineLiver enzyme elevationCare of patientsConfirmation of diagnosisEducation of patientsCounseling of patientsDominant polycystic kidney diseasePolycystic kidney diseaseTolvaptan treatmentProgressive diseaseEnzyme elevationFunction declineKidney diseaseClinical trialsGeneral practitionersDrug treatmentTreatment efficacyPatientsTolvaptanUS Food
2015
Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy
Alam A, Dahl NK, Lipschutz JH, Rossetti S, Smith P, Sapir D, Weinstein J, McFarlane P, Bichet DG. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy. American Journal Of Kidney Diseases 2015, 66: 564-576. PMID: 25960302, DOI: 10.1053/j.ajkd.2015.01.030.Peer-Reviewed Original ResearchConceptsTotal kidney volumeAutosomal dominant polycystic kidney diseaseDisease progressionKidney enlargementKidney functionClinical trialsKidney volumeEnd pointAutosomal dominant polycystic kidneyKidney function measuresPrognostic end pointProgressive kidney enlargementEfficacy end pointGlomerular filtration rateDominant polycystic kidney diseasePolycystic kidney diseaseFluid-filled cystsKidney diseaseFiltration rateCurrent evidencePolycystic kidneysCyst growthFibrotic tissueTherapeutic efficacyTherapeutic interventions